MAPT and Alzheimer disease: In patients with AD, APOE ε4 carrier status showed a significant correlation with the genetic variant rs242557 (p = 0.029, OR = 4.862, 95%CI (1.171–20.187)) and rs2471738 (p = 0.043, OR = 6.4, 95%CI (1.063–38.798)) located in the MAPT gene, both assuming a heterozygote model.